Loughborough University The Centre for Biological Engineering Doc Ref: FS008.1 : HTA-PR-FORM/007 Acquisition and Receipt of Biological Materials Issue Date:

ARF No: CBE/ARF/000 73

PART A: To be completed by the R	eceive	r (a separate f	form must be co	ompleted for e	ach sample ty	/pe)		
A1. Details of Sample/Specimen								
Type/ID: (eg primary cell, cell line, tissue, body fluid, excreta, biological agent)		Human Cord Blood (Ficolled) CD34+ isolation					⊠Human □Animal	
Format / Quantity: (eg vials, slides, etc		2x50mL tube containing ~21mL ficol unit. 2 donors total						
Tissue site/Organ source:	te/Organ source: Cord Blood							
Batch N°:								
Is the sample/specimen considered to be Relevant Material under the Human Tissue Act (HTA)? If No, go to section A2.							⊠Yes □No	
Is the material obtained from an H	use?	⊠Yes □No						
Is the material obtained for storag		□Yes⊠No						
Is the material licensable under the HTA? Indicate source below:							⊠Yes □No	
⊠HTA licensed organisation ⊠Co	mmer	cial Supplier	☐ Imported (fro	m outside Engl	and, Wales o	r N.Ireland)		
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID	Lot N°: G221222205730, G221222205735			Assigned Unique ID (Procuro): S00278648, S00278649				
Yes, provide Project Ref N°: BRA060 & BR			RA010					
If Yes, provide the name of the PI:	Dr Rob Thomas							
A2. Details of Receipt						,		
Date/Time of receipt		Date	21/10/2022		Time:	16:00		
ID of Receiver		Name:	Jon Harriman		Dept:	СВЕ		
ID of Supplier/Provider		Name:	Anthony Nolan		Country:	UK		
PART B: To be completed by the l	Receiv	er						
B1. Inspection and Quarantine								
Has a biological risk assessment for the use of this material been approved?			⊠Yes □No	Ref Number:	Ref Number: BRA060 & BRA010			
Physical integrity of the material(s) acceptable?			⊠Yes □No	If No, describe action taken				
Quantity received correct?			⊠Yes □No	If No, describe action taken				
Labelling correct and legible?			⊠Yes □No	If No, describe action taken				
Is the relevant documentation attached to this form? C of A or equivalent quality				⊠Yes □No □N/A				
If No. add reference or details		eements to enable transfer of erial eg MTA, SLA						
to ensure traceability		tails/evidence/assurance of ⊠Yes □No □N/A nsent			□IV/A		2 4 62	

	Other (describe	De) □Yes □No □N/A			
Temporary storage -	Building/Room		Received 16:00 21/11/22. Stored in HTA box in lab cold room overnight. Processed 22/11/22 (H21, JH) into 2x Mixed donor 1mL vials @4.08E6. Frozen via passive cooling in H34 -80C ULT freezer until 23/11/22 and transferred to LN2 cryo-bank.		
Quarantine location (as applicable)	Storage Unit ID)	4Fri-HTA & Cryo-HTA	Surk.	
	Within storage	unit location ID			
	Date/Time of q	uarantine	Bank 7 Rack 5 Box A 14,15 23/11/2022 12:00		
Submitted by:	Signature:		Date: 22/11/21		
PART C: To be completed by the	departmental Q	uality Manager			
C1. Quality Assurance Checks					
Has the sample/specimen been se	☐Yes ☐No ☐N/A				
Has the donor been screened for	☑Yes □No □N/A				
Has the sample/specimen been so	□Yes □No □N/A				
Is there evidence that the supplie or other recognised certification?	UYes □No □N/A				
For HTA licensable material, is the and use of the material under the	☑Yes □No □N/A				
Is there sufficient evidence to sup	□Yes □NO □N/A				
C2. Approval for release from qua					
Can the material be released from released for processing?	າ quarantine and	transferred to desig	nated storage area or	□Yes □No	
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐Accept as is, but	t with extra controls		
		☐ Rework or reprospecified requirem			
		☐Test to meet spe	ecified requirements		
		☐ Return to suppli	er/provider	1	
	□Disposal				
If Yes, provide details of storage location (as applicable)		Building/Room			
		Storage Unit ID			
		Within storage uni	t location ID	1.0	
		Database Reference	ce	HS above	
		Date/Time of trans	ifer		
Approved by:		Signature:		Date: 22/11/22	